Anti-CD3 monoclonal antibody
An anti-CD3 immunosuppresive drugs.
The first to be approved was muromonab-CD3 in 1986, to treat transplant rejection.
Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab. They are being investigated for the treatment of other conditions like Crohn's disease, ulcerative colitis and type 1 diabetes,[1] and for inducing immune tolerance.[2][3]
Mechanism of action
See muromonab-CD3.
See also
- List of monoclonal antibodies
References